|
|
|
xtalks.com, webinar
Thursday, February 24, 2022 | 1pm EST
Who Should Attend?This webinar will appeal to: - Neurologists
- Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, bio-pharma companies as well as universities and research institutes working in:
- Biomarker discovery/development
- Biomarkers for Neurological disorders
- Clinical Biomarkers
- Companion Diagnostics
- Personalized Medicine
- Tailored Therapeutics
- Translational Medicine and Science
What You Will LearnAttendees will learn about the current information on important biomarkers for Alzheimer’s disease and the utility of each based on clinical evidence and how these markers impact current and future treatment options.
|
|
|
|
|
|
Organized by:
|
|
xtalks.com |
|
Invited Speakers:
|
|
SpeakersKatherine T. Landschulz, PhD, Sr Director and Therapeutic Area Lead, Neurodegenerative Diseases, Labcorp Biomarker Solution CenterAs Neurodegeneration Therapeutic Area Lead for the Labcorp Biomarker Solution Center, Dr. Landschulz is responsible for the delivery of biomarker strategies for sponsor programs in Alzheimer’s, Parkinson’s and other neurodegenerative disease indications. Dr. Landschulz serves as a consultant to sponsors and teams, advising regarding biomarker selection and strategy development, laboratory placement of testing, feasibility designs, and overall guidance around translational and exploratory biomarker data in drug development. Dr. Landschulz serves further as a liaison, directing questions and connecting sponsor and Labcorp biomarker scientists. Finally, Dr. Landschulz participates in enterprise-wide assessments, licensing and implementation of new laboratory biomarker and tests transitioning from clinical trial to clinical care utilization. Message PresenterJohn W. Winslow, PhD. Director of Research and Development, Labcorp-Monogram BiosciencesDr. Winslow is Director, R&D; Labcorp/Monogram Biosciences laboratory, and heads a group that is responsible for the innovation, development and validation of diagnostic assays supporting biomarker-guided, personalized neurology and oncology patient treatment. Dr. Winslow and group also actively develop and apply biomarker testing to support pharmaceutical/biotechnology company pre-clinical and clinical evaluation of novel therapeutics. Dr. Winslow is an enterprise-wide contributor to multiple R&D committees and project teams assessing emerging technologies for further evaluation, licensing and implementation, primarily in neurology and oncology. He is an active participant in several major scientific conferences and frequently presents results from collaborative biomarker assay development and translational studies. Dr. Winslow is a co-author of over 60 peer-reviewed scientific publications, and 20 issued patents. Message Presente
|
|
|
|
|
|
Deadline for Abstracts:
|
|
na
|
|
|
|
|
|
Registration:
|
|
https://xtalks.com/webinars/a-review-of-current-biomarkers-for-alzheimers-disease/
|
|
E-mail:
|
|
shunte@xtalks.com
|
|
|
|
|
|
|
|